Last updated: September 9, 2026
Cobicistat/darunavir ethanolate is marketed in the United States as Prezcobix, a fixed-dose HIV-1 treatment developed by Janssen Pharmaceuticals. The product combines darunavir, an HIV protease inhibitor, with cobicistat, a pharmacokinetic enhancer that raises darunavir exposure. Its commercial position is durable but mature. Growth is constrained by once-daily integrase-inhibitor regimens, especially Gilead’s Biktarvy, while the product retains value in treatment-experienced patients, boosted-protease-inhibitor treatment, and combination regimens such as Symtuza.
Prezcobix received U.S. Food and Drug Administration approval on July 29, 2015. It contains 800 mg of darunavir and 150 mg of cobicistat per tablet and is indicated with other antiretroviral agents for treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg.[1]
What is the commercial market for cobicistat and darunavir ethanolate?
The commercial market consists of three related products:
| Product |
Ingredients |
Primary company |
Market role |
| Prezcobix |
Darunavir/cobicistat |
Janssen |
Two-drug boosted protease-inhibitor regimen |
| Symtuza |
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide |
Janssen and Gilead collaboration |
Complete single-tablet regimen |
| Prezista plus Tybost |
Darunavir plus cobicistat supplied separately |
Janssen and Gilead |
Flexible combination therapy |
Darunavir provides antiviral activity by inhibiting HIV protease. Cobicistat has no meaningful antiviral activity by itself. It inhibits CYP3A-mediated metabolism and increases darunavir concentrations, allowing once-daily administration.
The product competes in a mature HIV antiretroviral market where treatment guidelines increasingly favor integrase strand transfer inhibitor regimens. The U.S. Department of Health and Human Services lists bictegravir- and dolutegravir-based regimens among preferred initial treatment options for most people with HIV, while boosted protease-inhibitor regimens remain relevant when resistance, prior treatment history, or drug-interaction considerations affect regimen selection.[2]
How does Prezcobix compare with competing HIV treatments?
Prezcobix has a stronger position in treatment-experienced HIV than in first-line treatment.
| Regimen |
Commercial advantage |
Principal limitation |
| Prezcobix |
High genetic barrier associated with darunavir; once-daily dosing |
Requires other antiretroviral agents and has CYP3A interaction restrictions |
| Symtuza |
Complete single-tablet regimen with darunavir-based resistance profile |
Higher product complexity and exposure to TAF-related class competition |
| Biktarvy |
Strong first-line adoption, single-tablet dosing, high commercial scale |
Less differentiated in some heavily treatment-experienced or resistance-selected patients |
| Tivicay-based combinations |
Broad use and low pill burden |
Integrase resistance and interaction considerations in selected settings |
| Generic darunavir plus a pharmacokinetic enhancer |
Potentially lower cost |
Fixed-dose convenience and generic availability vary by jurisdiction |
Biktarvy and other integrase-based products have shifted market share away from boosted protease-inhibitor products. Gilead reported Biktarvy product sales of approximately $11.85 billion in 2023, demonstrating the scale of the competing integrase segment.[3]
Prezcobix is therefore less dependent on new HIV diagnoses than on treatment switching, resistance management, payer coverage, and continued use of darunavir-based therapy.
What is the FDA regulatory status of cobicistat/darunavir?
Prezcobix is an FDA-approved prescription product for HIV-1 treatment. It is not a biologic and therefore has no biosimilar pathway. Any future competitor would generally proceed through the abbreviated new drug application pathway for a small-molecule generic, subject to pharmaceutical equivalence, bioequivalence, labeling, and patent certification requirements.
Key U.S. regulatory milestones include:
| Date |
Event |
| July 29, 2015 |
FDA approved Prezcobix |
| 2016 |
Janssen expanded pediatric labeling for eligible patients |
| 2018 |
FDA approved Symtuza, a related darunavir/cobicistat fixed-dose combination with emtricitabine and TAF |
| Ongoing |
Labeling remains constrained by CYP3A drug interactions, renal considerations, and hepatitis B treatment requirements associated with the full regimen |
Prezcobix is not a complete antiretroviral regimen. The FDA label requires administration with other antiretroviral agents.[1] Symtuza is commercially stronger as a complete single-tablet regimen because it combines darunavir/cobicistat with two nucleoside reverse transcriptase inhibitors.
What patents protect Prezcobix and darunavir/cobicistat?
Protection for the product comes from several layers rather than one molecule patent:
- Darunavir composition and solid-state protection.
- Cobicistat composition and formulation protection.
- Combination-product patents covering darunavir with a pharmacokinetic enhancer.
- Tablet formulation and manufacturing claims.
- Method-of-use claims covering HIV treatment and dosing.
- Patents associated with related products, including Symtuza.
The original darunavir molecule is substantially older than Prezcobix. As a result, the principal commercial risk is not loss of all darunavir protection at one time. The more important question is whether enforceable combination, formulation, or pediatric patents delay approval or launch of a fixed-dose generic.
The FDA Orange Book lists patents and exclusivity information for approved products but does not guarantee that every listed claim will withstand validity or infringement challenges.[4] Patent expiration dates can also differ by patent, pediatric extension, terminal disclaimer, patent-term adjustment, and jurisdiction.
What formulations are protected by the Prezcobix patent estate?
The commercially relevant formulation is an oral fixed-dose tablet containing darunavir and cobicistat. Protection may extend to:
- Specific active-ingredient ratios.
- Tablet composition and excipients.
- Stability and dissolution characteristics.
- Methods for administering boosted darunavir once daily.
- Combination use with other antiretroviral agents.
Formulation patents matter because a generic applicant could face a more difficult path when the active ingredients are old but the approved fixed-dose combination has later-developed formulation claims.
When does Prezcobix lose exclusivity?
Prezcobix does not have one single loss-of-exclusivity date.
The product’s FDA approval date was 2015, but patent protection can extend beyond the basic five-year new chemical entity exclusivity period because the active ingredients were previously known or approved separately. The commercial exclusivity timeline is therefore determined by the remaining Orange Book patents and any settlements with generic applicants.
A practical exclusivity framework is:
| Protection layer |
Commercial effect |
| New chemical entity exclusivity |
Limited or unavailable for the fixed-dose combination because darunavir and cobicistat were previously known |
| Combination-product patents |
Can delay approval or launch of generic darunavir/cobicistat |
| Formulation patents |
Can create additional litigation risk |
| Pediatric exclusivity |
Can add six months to eligible patent or exclusivity periods |
| Regulatory exclusivity |
Generally less important than patent protection for this product |
| Global patents |
Expire on different dates and have different enforceability |
Publicly available FDA records should be used for the operative U.S. Orange Book entries immediately before any launch, transaction, or litigation decision. A single headline expiration date would be misleading because Prezcobix, Prezista, Tybost, and Symtuza have separate listings and patent estates.
Has Prezcobix faced Paragraph IV challenges?
A Paragraph IV certification allows an ANDA applicant to assert that a listed patent is invalid, unenforceable, or not infringed. A generic applicant’s notice letter can trigger Hatch-Waxman litigation and, in some circumstances, a 30-month stay of FDA approval.
The relevant commercial issue is whether an ANDA applicant challenges the fixed-dose combination patents, not merely whether darunavir or cobicistat is individually old. A generic version of darunavir alone would not automatically establish substitutability for Prezcobix.
No FDA-approved generic fixed-dose darunavir/cobicistat product is identified in the FDA product records cited here.[4] The absence of an approved generic does not establish that no ANDA has been filed or that no Paragraph IV notice has been issued. It does indicate that generic substitution had not become an established U.S. market event in the cited regulatory record.
What is the Orange Book status of Prezcobix?
Prezcobix is an FDA-approved small-molecule product with Orange Book-listed patent information. The Orange Book is the controlling public reference for listed U.S. patents and exclusivity associated with the approved product.[4]
The Orange Book analysis should distinguish among:
- Prezcobix fixed-dose patents.
- Prezista darunavir patents.
- Tybost cobicistat patents.
- Symtuza combination patents.
- Patent-term extensions and pediatric extensions.
- Patents listed against the active product versus patents listed against related products.
For valuation, the most important question is whether a generic applicant can launch a therapeutically substitutable fixed-dose product before all relevant combination and formulation patents expire or are resolved.
What is the financial trajectory for cobicistat/darunavir?
Janssen does not generally report Prezcobix revenue as a stand-alone public line item. Johnson & Johnson reports pharmaceutical sales by therapeutic area and product group, while HIV revenue can include several products and markets.[5] The lack of separate Prezcobix disclosure limits precise product-level revenue modeling.
The financial trajectory is best characterized in four phases.
2015-2018: Launch and regimen migration
Prezcobix expanded access to once-daily boosted darunavir in a fixed-dose tablet. Its value came from improved pill burden relative to separate darunavir and booster administration and from the established clinical profile of darunavir.
2018-2021: Portfolio expansion through Symtuza
Symtuza gave the darunavir franchise a complete single-tablet product. This reduced the strategic role of Prezcobix as a standalone two-drug component, but it also broadened the franchise’s ability to retain patients within a darunavir-based regimen.
2021-2024: Mature-product pressure
The market shifted toward integrase inhibitor products, especially Biktarvy and dolutegravir-based combinations. Prezcobix remained commercially relevant in treatment-experienced patients, but new-patient share and pricing power faced pressure from high-volume competing regimens.
2025 and later: Erosion risk depends on fixed-dose generic entry
The largest financial inflection point is generic entry for darunavir/cobicistat or a clinically substitutable regimen. Prezcobix revenue would likely decline in a stepwise pattern if a generic fixed-dose product achieved broad payer coverage. Erosion could be slower if:
- Generic entry is limited to separate components.
- Combination patents remain enforceable.
- Payers preserve branded access for selected patients.
- Darunavir’s treatment-experienced niche remains clinically important.
- Janssen shifts patients toward Symtuza or other branded portfolio products.
Which companies compete with Janssen?
The competitive landscape includes originator HIV manufacturers and generic antiretroviral companies.
| Company |
Relevant competitive products or capabilities |
| Gilead Sciences |
Biktarvy, Genvoya, Stribild, Symtuza collaboration and HIV portfolio |
| ViiV Healthcare |
Tivicay, Triumeq, Dovato, Cabenuva |
| Merck |
Isentress and HIV development capabilities |
| Teva, Mylan/Viatris, Lupin, Cipla, and other generics companies |
Potential suppliers of individual or fixed-dose antiretroviral products, subject to approval and patent status |
Gilead is the most important commercial competitor because of Biktarvy’s scale and its involvement in Symtuza. ViiV competes through integrase-based regimens and long-acting treatment. Generic manufacturers represent the principal future price-disruption risk.
How strong is the patent estate for Prezcobix?
The patent estate is moderately strong commercially but weaker than the estate for a new molecular entity launched with long remaining composition-of-matter protection.
Its strengths are:
- Darunavir’s clinical value in resistant HIV.
- Combination and formulation protection around the fixed-dose product.
- A branded portfolio that includes Prezcobix and Symtuza.
- Physician familiarity with darunavir-based treatment.
Its weaknesses are:
- Older underlying active ingredients.
- Strong competition from integrase inhibitors.
- No biosimilar barrier.
- Potentially limited value of method-of-use patents against generic prescribing.
- Lack of separately disclosed product revenue, which makes exposure assessment less precise.
Method-of-use patents are often less effective commercially than composition or formulation patents because generic applicants can use labeling strategies, carve-outs, or non-infringing indications. Their practical value depends on the specific claim language and the approved generic label.
What generic launch scenarios exist?
Three scenarios are commercially relevant.
Scenario 1: No near-term fixed-dose generic
Prezcobix retains branded sales, with gradual decline from treatment switching and portfolio migration to Symtuza or integrase products.
Scenario 2: Limited generic entry
A generic entrant launches after patent resolution but receives restricted payer coverage. Price erosion is material but slower than in a fully commoditized market.
Scenario 3: Broad generic substitution
One or more ANDA-approved products obtain formulary placement and pharmacy substitution. Prezcobix experiences rapid price and volume erosion, while Janssen retains selected patients through clinical preference, contracting, or movement to Symtuza.
The most likely economic outcome for mature HIV products is portfolio-level erosion rather than complete loss of franchise revenue. Patients may switch among Janssen products, while the overall darunavir franchise faces pressure from integrase inhibitors and lower-cost competitors.
What geographic markets matter?
The United States is the most important market for patent-linked economics because of branded pricing, Orange Book listings, and Hatch-Waxman litigation. Europe is more exposed to national reimbursement decisions, centralized or decentralized procurement, and earlier generic substitution after patent expiry. Lower- and middle-income markets are heavily influenced by voluntary licensing, procurement agreements, generic competition, and public-health programs.
The global value of cobicistat/darunavir is therefore less concentrated in product-level price than in access agreements, treatment guidelines, and the size of the treatment-experienced HIV population.
Key Takeaways
- Prezcobix is the U.S. fixed-dose darunavir/cobicistat product marketed by Janssen.
- Its principal clinical advantage is darunavir’s role in treatment-experienced and resistance-relevant HIV care.
- Integrase inhibitor regimens, led commercially by Biktarvy, are the main source of market-share pressure.
- Symtuza protects and extends the broader darunavir franchise but reduces the standalone strategic importance of Prezcobix.
- The product is a small molecule with no biosimilar risk.
- Generic risk depends on the remaining Orange Book patents covering the fixed-dose combination, formulation, and methods of use.
- No FDA-approved generic fixed-dose darunavir/cobicistat product is identified in the cited FDA records.
- Janssen does not publicly disclose Prezcobix revenue as a distinct line item, limiting precise product-level financial modeling.
- The expected financial trajectory is mature-product decline, with the slope determined by generic timing, payer adoption, and migration within Janssen’s HIV portfolio.
FAQs
Is cobicistat itself an HIV treatment?
No. Cobicistat is a pharmacokinetic enhancer. It increases exposure to antiretroviral drugs such as darunavir but does not provide meaningful antiviral activity as monotherapy.
Is Prezcobix the same as Symtuza?
No. Both contain darunavir and cobicistat. Prezcobix contains only those two active ingredients, while Symtuza also contains emtricitabine and tenofovir alafenamide and is a complete single-tablet regimen.
Can generic darunavir replace Prezcobix?
Not automatically. Generic darunavir alone does not provide the cobicistat component or the same fixed-dose tablet. Substitution depends on the product approved, the prescription, state law, payer policy, and clinical requirements.
Why does darunavir remain valuable despite integrase inhibitor competition?
Darunavir has a high genetic barrier to resistance and remains useful for certain treatment-experienced patients, patients with resistance mutations, and cases where clinicians prefer a boosted protease-inhibitor regimen.
What would most reduce Prezcobix revenue?
Broad payer adoption of an FDA-approved generic fixed-dose darunavir/cobicistat product would create the sharpest direct revenue risk. Continued migration to integrase inhibitor regimens is the largest ongoing indirect risk.
References
- U.S. Food and Drug Administration. (2015). Prezcobix (darunavir and cobicistat) prescribing information.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services.
- Gilead Sciences, Inc. (2024). 2023 annual report.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Johnson & Johnson. (2024). 2023 annual report.
